Siegfried, a leading global Contract Development and Manufacturing Organization with head-quarters in Zofingen, Switzerland, today broke ground and celebrated the start of the construction of its new large-scale production plant in Minden, Germany. The planned production plant, for which Siegfried will invest up to CHF 100 million, is the largest building project in the company's history. The new facility, which is expected to start operations in 2024, will host up to 100 m³ additional reactor capacity. This will not only significantly increase the capacity of Siegfried's drug substance business, but also expand the technological capabilities and the flexibility of Siegfried's global network. Siegfried will thus be able to become an even more attractive partner for customers in the pharmaceutical industry and to further strengthen its competitive position. The plant is built using the latest technology and applying the high standards of sustainability. It will serve as the blueprint for all future investments of the group.

Wolfgang Wienand, CEO of Siegfried said at the ground-breaking ceremony: "We have grown successfully in a very challenging environment over the past years and want to continue on this path. The new facility in Minden will help us to become an even more attractive partner for our customers. Minden offers us an ideal environment for this major investment, and we look forward to offering even more exciting jobs here in the future."

Achim Post, Member of the Bundestag for Minden-Lübbecke: "Siegfried's investment in the Minden site demonstrates that we offer an attractive and globally competitive environment here in the region, with well-qualified employees and a high-quality network of suppliers. It is therefore great to see such a state-of-the-art production facility being built here. I wish Siegfried continued success."

With this new plant, Siegfried is also strengthening Germany as a production location, where the company in Minden and Hameln employs close to 1000 employees. At its two German sites, Siegfried is manufacturing a wide range of pharmaceutical API as well as drug products. In Hameln, the vaccine against the coronavirus from Pfizer/BioNTech is filled, among other things.

Siegfried, a leading global Contract Development and Manufacturing Organization with head-quarters in Zofingen, Switzerland, today broke ground and celebrated the start of the construction of its new large-scale production plant in Minden, Germany. The planned production plant, for which Siegfried will invest up to CHF 100 million, is the largest building project in the company's history. The new facility, which is expected to start operations in 2024, will host up to 100 m³ additional reactor capacity. This will not only significantly increase the capacity of Siegfried's drug substance business, but also expand the technological capabilities and the flexibility of Siegfried's global network. Siegfried will thus be able to become an even more attractive partner for customers in the pharmaceutical industry and to further strengthen its competitive position. The plant is built using the latest technology and applying the high standards of sustainability. It will serve as the blueprint for all future investments of the group.

Wolfgang Wienand, CEO of Siegfried said at the ground-breaking ceremony: "We have grown successfully in a very challenging environment over the past years and want to continue on this path. The new facility in Minden will help us to become an even more attractive partner for our customers. Minden offers us an ideal environment for this major investment, and we look forward to offering even more exciting jobs here in the future."

Achim Post, Member of the Bundestag for Minden-Lübbecke: "Siegfried's investment in the Minden site demonstrates that we offer an attractive and globally competitive environment here in the region, with well-qualified employees and a high-quality network of suppliers. It is therefore great to see such a state-of-the-art production facility being built here. I wish Siegfried continued success."

With this new plant, Siegfried is also strengthening Germany as a production location, where the company in Minden and Hameln employs close to 1000 employees. At its two German sites, Siegfried is manufacturing a wide range of pharmaceutical API as well as drug products. In Hameln, the vaccine against the coronavirus from Pfizer/BioNTech is filled, among other things.

Siegfried, a leading global Contract Development and Manufacturing Organization with head-quarters in Zofingen, Switzerland, today broke ground and celebrated the start of the construction of its new large-scale production plant in Minden, Germany. The planned production plant, for which Siegfried will invest up to CHF 100 million, is the largest building project in the company's history. The new facility, which is expected to start operations in 2024, will host up to 100 m³ additional reactor capacity. This will not only significantly increase the capacity of Siegfried's drug substance business, but also expand the technological capabilities and the flexibility of Siegfried's global network. Siegfried will thus be able to become an even more attractive partner for customers in the pharmaceutical industry and to further strengthen its competitive position. The plant is built using the latest technology and applying the high standards of sustainability. It will serve as the blueprint for all future investments of the group.

Wolfgang Wienand, CEO of Siegfried said at the ground-breaking ceremony: "We have grown successfully in a very challenging environment over the past years and want to continue on this path. The new facility in Minden will help us to become an even more attractive partner for our customers. Minden offers us an ideal environment for this major investment, and we look forward to offering even more exciting jobs here in the future."

Achim Post, Member of the Bundestag for Minden-Lübbecke: "Siegfried's investment in the Minden site demonstrates that we offer an attractive and globally competitive environment here in the region, with well-qualified employees and a high-quality network of suppliers. It is therefore great to see such a state-of-the-art production facility being built here. I wish Siegfried continued success."

With this new plant, Siegfried is also strengthening Germany as a production location, where the company in Minden and Hameln employs close to 1000 employees. At its two German sites, Siegfried is manufacturing a wide range of pharmaceutical API as well as drug products. In Hameln, the vaccine against the coronavirus from Pfizer/BioNTech is filled, among other things.